南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

IL-17D可重编程胶质母细胞瘤微环境中的CD93+抗原呈递细胞

IL-17D reprograms CD93+ antigen-presenting cells in the glioblastoma microenvironment

Tang Weijie, Zhang Shuyuan, Qi Yanhua, Li Boyan, Gao Zijie, Pan Ziwen, Qiu Jiawei, Xue Hao, Li Gang, Wang Shaobo

Journal:Cellular & Molecular Immunology

IF:23.9

DOI:10.1038/s41423-026-01458-z

PMID:42595853

Published:2026-08-13

research field:分子生物学进化生物学环境科学遗传学遗传学与基因组学植物科学

Abstract

The immunosuppressive microenvironment is a hallmark of glioblastoma (GBM), limiting the efficacy of contemporary immunotherapies. While the central nervous system (CNS) relies on specialized cytokine networks to maintain immune homeostasis under physiological conditions, how these homeostatic signals are subverted during gliomagenesis remains poorly understood. Here, we report that interleukin-17D (IL-17D) is a CNS-intrinsic tumor suppressor whose expression is downregulated during gliomagenesis. Restoring IL-17D substantially extends survival in orthotopic GBM models by selectively reprogramming the myeloid compartment. Mechanistically, IL-17D engages its receptor CD93 to assemble a novel costimulatory receptor complex with SCARB1 in a lipid raft-dependent manner. This structural assembly engages Fyn/BCAP to trigger PI3K/AKT/NF-κB signaling, effectively inverting the function of SCARB1 from tolerogenic efferocytosis to active antigen presentation. Our study demonstrated that the restoration of IL-17D expression reshaped the GBM immune landscape, highlighting its potential as a therapeutic target to enhance the efficacy of immunotherapy.

本文使用的Yeasen产品

购物车
客服
转染试用